JP2024541013A - タダラフィル経口懸濁剤 - Google Patents
タダラフィル経口懸濁剤 Download PDFInfo
- Publication number
- JP2024541013A JP2024541013A JP2024524693A JP2024524693A JP2024541013A JP 2024541013 A JP2024541013 A JP 2024541013A JP 2024524693 A JP2024524693 A JP 2024524693A JP 2024524693 A JP2024524693 A JP 2024524693A JP 2024541013 A JP2024541013 A JP 2024541013A
- Authority
- JP
- Japan
- Prior art keywords
- tadalafil
- sodium
- cyclodextrin
- composition
- comprised
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382964 | 2021-10-25 | ||
| EP21382964.1 | 2021-10-25 | ||
| PCT/EP2022/079659 WO2023072872A1 (en) | 2021-10-25 | 2022-10-24 | Tadalafil oral suspension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024541013A true JP2024541013A (ja) | 2024-11-06 |
| JP2024541013A5 JP2024541013A5 (enExample) | 2025-11-04 |
Family
ID=78528864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524693A Pending JP2024541013A (ja) | 2021-10-25 | 2022-10-24 | タダラフィル経口懸濁剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250241911A1 (enExample) |
| EP (1) | EP4422599B1 (enExample) |
| JP (1) | JP2024541013A (enExample) |
| CN (1) | CN118284408A (enExample) |
| AU (1) | AU2022374786A1 (enExample) |
| CA (1) | CA3235733A1 (enExample) |
| DK (1) | DK4422599T3 (enExample) |
| FI (1) | FI4422599T3 (enExample) |
| MX (1) | MX2024005048A (enExample) |
| WO (1) | WO2023072872A1 (enExample) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7018658B2 (en) | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
| US20060147531A1 (en) | 2003-07-01 | 2006-07-06 | Mojca Segula | Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate |
| SI21637A (sl) | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtska oblika z nadzorovanim sproščanjem |
| KR20070021806A (ko) | 2005-08-19 | 2007-02-23 | (주)아모레퍼시픽 | α1-수용체 차단제의 서방형 펠렛제제 및 이의 제조 방법 |
| KR100745515B1 (ko) | 2006-04-10 | 2007-08-02 | 주식회사 대웅제약 | 염산 탐술로신 함유 서방성 펠렛 및 그의 제조방법 |
| KR20160021095A (ko) | 2013-06-21 | 2016-02-24 | 욱크하르트 리미티드 | 탐술로신 또는 이의 염의 약학 조성물 |
| CZ2015225A3 (cs) | 2015-03-30 | 2016-10-12 | Zentiva, K.S. | Nový krok ve způsobu potahování pelet obsahujících Tamsulosin.HCI |
| EP3498264B1 (en) * | 2016-08-12 | 2023-11-08 | Hanmi Pharm. Co., Ltd. | Pharmaceutical preparation for oral administration with controlled dissolution rate, the preparation comprising tamsulosin hydrochloride-containing sustained-release pellets |
| EP3576741A1 (en) | 2017-02-02 | 2019-12-11 | Dukebox SP. Z O.O. | A method of manufacturing a suspension of nanoparticles of tadalafil or sildenafil citrate |
| EP3473245A1 (en) | 2017-10-20 | 2019-04-24 | Veru Inc. | Controlled release oral tamsulosin hydrochloride |
| WO2020039263A2 (en) | 2018-08-18 | 2020-02-27 | Ftf Pharma Private Limited | Pharmaceutical suspension for oral dosage |
-
2022
- 2022-10-24 US US18/703,099 patent/US20250241911A1/en active Pending
- 2022-10-24 MX MX2024005048A patent/MX2024005048A/es unknown
- 2022-10-24 DK DK22809383.7T patent/DK4422599T3/da active
- 2022-10-24 CN CN202280077312.5A patent/CN118284408A/zh active Pending
- 2022-10-24 CA CA3235733A patent/CA3235733A1/en active Pending
- 2022-10-24 AU AU2022374786A patent/AU2022374786A1/en active Pending
- 2022-10-24 EP EP22809383.7A patent/EP4422599B1/en active Active
- 2022-10-24 WO PCT/EP2022/079659 patent/WO2023072872A1/en not_active Ceased
- 2022-10-24 FI FIEP22809383.7T patent/FI4422599T3/fi active
- 2022-10-24 JP JP2024524693A patent/JP2024541013A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250241911A1 (en) | 2025-07-31 |
| MX2024005048A (es) | 2024-05-10 |
| EP4422599A1 (en) | 2024-09-04 |
| DK4422599T3 (da) | 2026-03-30 |
| FI4422599T3 (fi) | 2026-03-25 |
| CN118284408A (zh) | 2024-07-02 |
| EP4422599B1 (en) | 2026-01-28 |
| AU2022374786A1 (en) | 2024-06-13 |
| WO2023072872A1 (en) | 2023-05-04 |
| CA3235733A1 (en) | 2023-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1239831B1 (en) | Improved pharmaceutical compositions for poorly soluble drugs | |
| CA2567075C (en) | Pharmaceutical suspension composition | |
| CA2393737A1 (en) | Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption | |
| CN119212736A (zh) | 水性替格瑞洛溶液、生产方法及用途 | |
| US8071133B2 (en) | Oral dosage forms of water insoluble drugs and methods of making the same | |
| EP4422599B1 (en) | Tadalafil oral suspension | |
| EP3644968B1 (en) | Levocloperastine fendizoate suspension having enhanced dissolution and resuspendability | |
| EP3968955A1 (en) | Pharmaceutical oral liquid solution of ivacaftor | |
| WO2004012714A1 (en) | Oral dosage forms of water insoluble drugs and methods of making the same | |
| TWI332403B (enExample) | ||
| CN114828829B (zh) | 包含布洛芬和去氧肾上腺素的液体组合物 | |
| US20250064798A1 (en) | Vilazodone composition, pharmaceutical preparation thereof, preparation therefor, and use thereof | |
| WO2023285981A1 (en) | Stable pharmaceutical liquid composition of nilotinib | |
| EP2138173A1 (en) | Pharmaceutical compositions comprising aminoadamantane derivatives | |
| CN113730350A (zh) | 一种磷酸二酯酶4抑制剂组合物 | |
| JP2025527261A (ja) | 新規製剤 | |
| WO2024211881A1 (en) | Rimegepant suspension | |
| US20240091367A1 (en) | Orally disintegrating palatable formulations of drotaverine and method of preparation thereof | |
| HK40096982A (zh) | 包含美洛昔康的医药组成物 | |
| CN119546305A (zh) | 泛raf激酶抑制剂的口服液体悬浮液 | |
| JP2025531270A (ja) | ベルモスジルの液体製剤 | |
| Namdev | Formulation and Evaluation of Mouth Dissolving Tablets of Metoprolol Tartrate | |
| Subhan | Development and evaluation of fast dissolving tablets of nimodipine | |
| EA041538B1 (ru) | Суспензия на основе левоклоперастина фендизоата с повышенными растворимостью и ресуспендируемостью | |
| WO2017214034A1 (en) | Oral liquid suspensions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251023 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251023 |